Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy.
Cardiovascular Department, Fondazione CNR Regione Toscana G. Monasterio, Via G Moruzzi 1, 56124, Pisa, Italy.
Curr Cardiol Rep. 2020 Aug 9;22(10):116. doi: 10.1007/s11886-020-01368-0.
PET myocardial perfusion imaging (MPI) is an established modality for the evaluation of ischemic heart disease and quantitation of myocardial blood flow (MBF). New F-18-labelled radiopharmaceuticals have been recently developed to overcome some of the limitations of currently used tracers such as the need of an on-site cyclotron. The characteristics of the new tracers and the clinical results obtained so far will be reviewed.
Most of the interest in the field of F-labelled radiotracers for PET MPI has been concentrated on MC-1 inhibitors, the prototype of which is F-flurpiridaz. It was shown in experimental and clinical reports that these radiotracers allow good quality rest/stress MPI studies and a reliable quantitation of MBF. Recent evidence suggests that PET MPI with F-flurpiridaz may provide a superior diagnostic accuracy for obstructive CAD even if a large comparative clinical trial with SPECT is still ongoing.
正电子发射断层扫描心肌灌注显像是评估缺血性心脏病和定量心肌血流的一种成熟的方法。最近开发了新型 F-18 标记放射性药物，以克服当前使用的示踪剂的一些局限性，例如需要现场回旋加速器。将综述新型示踪剂的特性和迄今为止获得的临床结果。
正电子发射断层扫描心肌灌注显影中 F 标记放射性示踪剂的研究主要集中在 MC-1 抑制剂上，其原型是 F-氟比拉嗪。实验和临床报告表明，这些放射性示踪剂可进行高质量的静息/负荷 MPI 研究，并可靠地定量心肌血流。最近的证据表明，即使仍在进行与单光子发射计算机断层扫描的大型对比临床试验，氟比拉嗪的正电子发射断层扫描心肌灌注显影也可能为阻塞性 CAD 提供更高的诊断准确性。
